london euretina

This meeting has been awarded 20 CME credits

Security Notice

Please note that Kuoni are our only destination management company. Other venders indicating that are operating for the society should be ignored. We never use western union as a payment portal

Posters

Serum hemoglobin (HbA1c) influence and diabetic macular edema improvement measured by OCT in patients treated with intravitreal ranibizumab

Poster Details

First Author: R.Abreu SPAIN

Co Author(s):    L. Pérez   L. Solé   M. Alonso   M.A. Gil   P. Abreu      0   0 0   0 0   0 0   0 0

Abstract Details



Purpose:

To evaluate the influence of serum hemoglobin (HbA1c) in the tomographic response intravitreal ranibizuamb treatment for diabetic macular edema.

Setting:

University Hospital of La Candelaria , Tenerife , Canary Islands, Spain

Methods:

Observational , retrospective, single-center study reviewing medical records of patients with diabetic macular edema, treated according to standard clinical practice intravitreal ranibizumab monotherapy , between August 2012 and August 2013. The primary outcome measure was change in central macular thickness measured with optical coherence tomography and its correlation with the values of HbA1c after treatment with intravitreal ranibizumab.

Results:

The study included 130 eyes (106 patients ); 70 ( 53.8 %) women and 60 ( 46.2%) men with a mean age of 68 +/-11 years . The mean HbA1c of the enrolled patients was 7.4+/-1.76% (range 4.4-11.7%). The mean value of best corrected visual acuity (BCVA) at baseline examination was 0.34 (logMAR ) , remaining unchanged with no statistically significant throughout the follow-up (3-12 months). The mean central subfield macular thickness (CSMT) at the baseline examination was 427 + / -133 microns and after ranibuzumab treatment was 359 + / -120 microns ( p<0.05). There was no statistical significance among: number of ranibizuamb injections received, change in CSMT, change in BCVA and the initial value of HbA1c.

Conclusions:

Daily clinical practice results of our center show that ranibizumab is an effective drug in the treatment of DME , these being independent of patients baseline HbA1c value.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy